We herein report a case of premature atherosclerosis in a patient with familial partial lipodystrophy (FPL), diabetes mellitus, hypertension and hypertriglyceridemia. Sequencing of the candidate genes LMNA, PPARG and CAV1 associated with FPL revealed no genetic abnormalities, which indicated the activity of a novel gene in this patient. The patient's son showed milder fat loss and similar fat distribution compared to the proband; however, the son showed no signs of any atherosclerotic disease. Although a cluster of atherogenic risk factors is likely to be the primary causes of atherosclerosis in our patient, other factors, including an unknown gene associated with FPL, the severity of fat loss and gender, might affect the development of atherosclerosis.
Introduction
Lipodystrophies are a heterogeneous group of diseases characterized by generalized or partial fat loss (1) (2) (3) (4) (5) . Some patients with partial lipodystrophies show fat hypertrophy in other locations. Lipodystrophy is diagnosed on the basis of fat loss in portions of the body determined with dual energy X-ray absorptiometry (DEXA) and magnetic resonance imaging (MRI) scans. Lipodystrophies are rare and have both inherited and acquired forms. Acquired lipodystrophies can be generalized or partial. Although the causes of acquired lipodystrophies are generally unknown, such acquired lipodystrophies can be associated with signs of autoimmunity. Patients with lipodystrophies often also have a cluster of associated diseases, including insulin resistance, dyslipidemia, hypertension, fatty liver and diabetes, similar to that observed in patients with metabolic syndrome. These patients often die of health problems, including ischemic heart disease, cerebral infarction, renal failure, severe liver dysfunction and pancreatitis. Congenital generalized lipodystrophies (CGLs) are autosomal recessive disorders that, in most patients, result from mutations in the genes encoding Seipin and 1-acylglycerol-3-phosphate-O-acyltransferase 2 (AG-PAT2) (6) . Familial partial lipodystrophies (FPLs) are autosomal dominant disorders, and mutations in the genes encoding laminin A/C, peroxisome proliferator-activated receptor-γ (PPARG) or caveolin have been reported in patients with FPL. Familial partial lipodystrophy, Dunnigan variety (FPLD) is named after Dunnigan, who provided a detailed description of the syndrome (7) . FPLD is associated with several mutations in the genes encoding laminin A/C. However, a number of patients with FPL remain undiagnosed at the genetic level.
Women with FPLD have a higher prevalence of diabetes and atherosclerotic vascular disease, higher serum triglyceride (TG) levels and lower high-density lipoprotein (HDL) cholesterol concentrations than men with FPLD (3, 9) . However, some patients with CGL or FPL do not have overt atherosclerotic diseases. Furthermore, the evidence for pre- 
Case Report
The patient was a 48-year-old woman. When she was 16 years old, she had a body mass index (BMI) of 36.5, which indicated obesity. At 35 years of age, she was diagnosed with diabetes by a family doctor based on the presence of high levels of hemoglobin A1c (HbA1c) and postprandial glucose. Her diabetes remained uncontrolled (HbA1c level: 8.0%-12.0%) despite treatment with a combination of 10 mg of glibenclamide and 0.6 mg of voglibose. At 40 years of age, she was transferred to the hospital emergency room due to convulsions and a disturbance of consciousness. Her magnetic resonance imaging (MRI, left panel) and magnetic resonance angiography (MRA, right panel) findings showed severe narrowing at the end of the internal carotid artery on both sides with an old cerebral infarction in the right anterior lobe (Fig. 3A, B) . The narrowing in the proximal region of the anterior and middle cerebral arteries on both sides is indicated by arrows. The presence of lesions suggested a diagnosis of premature atherosclerosis, because the patient had multiple atherogenic risk factors, including diabetes mellitus, hypertension and hypertriglyceridemia. However, we could not completely rule out moyamoya disease, because we did not perform a biopsy of the lesions that narrowed the arterial wall (10) . We initiated treatment with 160 mg of valsartan and 40 mg of Adalat-CR for hypertension in 2003 when the patient was 43 years old. Her blood pressure was reduced to 130/50 mmHg. Subsequently, superficial temporal artery-middle cerebral artery (STA-MCA) anastomosis was performed. The patient was admitted to our hospital for diabetes care in May 2007 when she was 48 years old. At that time, her height was 152 cm and she weighed 64 kg, which indicated a body mass index of 27.2. She did not have a history of either autoimmune or infectious diseases. She did not have a habit of smoking or consuming alcohol. She had entered menopause at the age of 40. Her HbA1c concentration was 6.5% (Table 1 ) and although her blood glucose level was found to be satisfactory on her first visit to our hospital, her dose of insulin was increased to 72 U/day (1.1 U/kg/day). Her serum TG level was 755 mg/dL and her HDL cholesterol level was 34 mg/dL; however, her blood glucose level was well-controlled. This suggested that the hypertriglyceridemia was due to insulin resistance. The patient did not have any other abnormal endocrinological findings, including abnormal cortisol levels. Her serum leptin level was 36.1 ng/mL, while her serum adiponectin level was 7.1 μg/mL. Her urinary C peptide level was 68. The patient had mild nonproliferative diabetic retinopathy. Her total urinary protein level was 1.0 g/day and her serum creatinine level was 1.06 mg/dL, which indicated overt diabetic nephropathy. An abdominal echo showed mild fatty liver and the L/S ratio of the computed tomography (CT) value was 1.3. The patient's serum albumin level, platelet count and hyaluronic acid level were within normal limits, which suggested that she did not have severe non-alcoholic steatosis hepatitis. She had noticed a loss of subcutaneous fat over her forearms, lower limbs and buttocks at 12 years of age. On admission, she showed loss of subcutaneous fat deposits in the forearms (right panel), lower limbs and buttocks, with prominent lower limb musculature and excess fat deposition around the face, neck and trunk (left panel, Fig. 1B ). The patient's mother and son showed a similar distribution of fat atrophy and we therefore considered an autosomal dominant pattern of inheritance (Fig. 1A) . The patient's condition was clinically diagnosed as FPL. The patient's mother was diagnosed with diabetes at 31 years of age and died of a cerebral infarction at 38 years of age. The patient's father died of chronic renal failure at the age of 75 and was not evaluated for fat atrophy or glucose tolerance. We assessed body fat distribution in the proband (Patient 1) in 2007 using DEXA and MRI studies. Thoracic (left panel) and abdominal MRI (right panel) revealed preservation of subcutaneous fat in the abdominal and thoracic regions ( Fig. 2A) . MRI images obtained at the level of the gluteal fat revealed a marked loss of gluteal subcutaneous fat (Fig. 2B) . Axial MRI performed at the level of the thigh (upper panel) and calf (lower panel) revealed a marked loss of subcutaneous fat in these regions (Fig. 2C) . Patient 1 had decreased amounts of subcutaneous fat, particularly in the antero-lateral and posterior thigh and calf regions. Axial MRI performed at the level of the forearms (lower panel) revealed almost a complete absence of subcutaneous fat in the forearms, while axial MRI performed at the level of the arms (upper panel) revealed the preservation of subcutaneous fat in this region (Fig. 2D) . The area of visceral fat located at the umbilical level measured 140.4 cm 2 . The regional and whole-body adipose tissue distribution and body composition estimated by the DEXA scan is shown in Table 2 . Compared to normal subjects, Patient 1 had markedly lower levels of fat in her legs, with prominent accumulation of fat in the trunk. She appeared to have well-preserved skeletal muscle.
The son of Patient 1 (Patient 2) was a 19-year-old man. His height was 163 cm and weight was 86.8 kg, thus suggesting a body mass index of 32.7. His blood pressure showed a normal range, and he did not have any health problems except for obesity. We assessed fat atrophy in various regions in Patient 2 using a DEXA scan and CT. As shown in Table 2 , we evaluated fat mass compared with two controls. The average BMI in Control Group 2, which included 72 healthy men between the ages of 20 and 29, was 22.4, while that in Control Group 3, which included 11 healthy men between the ages of 20 and 29, was 26.4. The finding of a BMI in Patient 2 of 32.7 kg/m 2 indicated that % fat and fat mass in one leg was relatively low, which suggested fat atrophy in the legs. The CT images of Patient 2 showed relatively low levels of subcutaneous fat in the thigh and buttocks (Fig. 4) . Patient 2 had a marked loss of subcutaneous fat, particularly in the lateral thigh, calf and forearm regions. Patients with FPL show marked losses of subcutaneous fat, particularly in the lateral thigh and calf regions (3). Therefore, the fat distribution pattern observed in Patient 2 seemed to be similar to that of his mother (Patient 1) and was consistent with the above observations. The area of visceral fat located at the umbilical level measured 69.5 cm 2 . Patient 2's fasting serum TG level was 125 mg/dL and his HbA1c level was 4.8%, both of which were within normal limits. An oral glucose tolerance test (OGTT) showed that Patient 2's blood glucose levels were 86, 111, 133 and 118 mg/dL, while his insulin levels were 5.6, 36.2, 92.9 and 68.8 μU/mL at 0, 30, 60 and 120 minutes. Therefore, the OGTT showed normal glucose levels with relatively high insulin levels. Both brain MRI and MRA showed normal results (data not shown). Therefore, Patient 2 did not have visceral obesity, hypertriglyceridemia, diabetes mellitus, hypertension or premature atherosclerosis, although he seemed to have partial lipodystrophy.
We examined the effects of pioglitazone on the metabolic values and the changes in lean mass and fat mass regions in Patient 1. We prescribed pioglitazone (15 mg/day) because thiazolidinediones have been reported to be effective for glycemic control in patients with FPL. We examined Patient 1's response to pioglitazone by monitoring her HbA1c levels and the changes in her biochemical data, body weight, fat and lean mass during treatment using DEXA. After three months of treatment, Patient 1's HbA1c level decreased from 9.2% to 7.1% and remained at approximately 7.0% thereafter, while her serum TG level decreased from 1,102 mg/dL to 431 mg/dL. After two weeks of pioglitazone treatment, the dose of insulin was reduced to 18 U/day (0.26 U/ kg/day). After three months, Patient 1's body weight increased from 67.0 to 78.0 kg. We decreased the dose of pioglitazone to 7.5 mg to prevent additional gains in body weight. The changes in fat and lean mass were monitored during pioglitazone treatment using DEXA scans. In addition, we evaluated the changes in the leptin and adiponectin levels during pioglitazone treatment. A comparison of the results of the DEXA scans showed that the fat mass increased by 2.6 kg, while the lean mass increased by 6.5 kg during pioglitazone treatment. Pioglitazone induced increases in fat mass predominantly in the trunk, and no increases were detectable in the lower limbs. After three months of treatment, the serum adiponectin level increased from 7.1 to 24.0 μg/mL and the HDL cholesterol level increased from 34 mg/dL to 45 mg/dL.
We examined the sequences of the entire coding region and the exon-intron boundary regions of the LMNA, PPARG and CAV1 genes, which are known to be associated with FPL; however, we found no mutations in these genes in the proband.
Discussion
We herein report the case of a 48-year-old Japanese woman (Patient 1) with diabetes and atypical FPL who showed marked losses of subcutaneous fat in the forearms, lower limbs and buttocks. The fat distribution pattern ob- 
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served in Patient 1 seemed to be similar to that seen in patients with atypical partial lipodystrophy with PPARG mutations (11-13). Patient 1 had been severely obese since 16 years of age. Her abdominal CT images showed visceral obesity. The age of onset of diabetes mellitus in Patient 1 was 35 years, which was relatively early compared to that observed in patients with type 2 diabetes mellitus. At 40 years of age, Patient 1 showed severe narrowing at the end of the internal carotid artery on both sides with an old cerebral infarction in the right anterior lobe, which suggested the presence of premature atherosclerosis. Because Patient 1 had visceral obesity and FPL, her intra-hepatic and intra-myocellular lipid contents may have been increased, which may have caused greater insulin resistance and worsened the atherosclerosis. The serum adiponectin levels are thought to be associated with the indices of insulin resistance and atherosclerosis (14, 15) . Patient 1's serum adiponectin level was 7.1 μg/mL. The data suggested that Patient 1's serum adiponectin levels were relatively lower than those in 28 women with normal glucose tolerance (16) . The level of adiponectin may also have had an effect on atherosclerosis in the case of Patient 1. Women with FPLD have a higher prevalence of diabetes and atherosclerotic vascular disease, higher serum TG levels and lower HDL cholesterol concentrations than men with FPLD (3, 9). Therefore, because Patient 1 was a woman with FPL and had a cluster of atherogenic risk factors, including diabetes mellitus, hypertension and hypertriglyceridemia, she had a predisposition for developing atherosclerosis. On the other hand, her son did not have premature atherosclerosis. The reasons for this were thought to be as follows: first, Patient 1's son was a 19-year-old man with a less severe amount of fat loss compared to his mother; second, he did not have hypertriglyceridemia, hypertension or diabetes mellitus, although he did have insulin resistance. We previously reported the case of a Japanese woman with diabetes with atypical FPL who had normal serum TG levels and did not have overt atherosclerosis (17) . Therefore, the severity of atherosclerosis in women with FPL seems to be variable, although the evidence for accelerated atherosclerosis in patients with FPL is minimal.
Hegele RA has also reported FPLD with the LMNA codon 482 mutation to be associated with an increased risk of developing early coronary heart disease (8) . In that report, the author speculated that LMNA mutations within arterial walls may affect the progression of atherosclerosis. In addition, we can speculate that an unidentified gene may affect arterial walls, which may have accelerated the progression of atherosclerosis in the case of Patient 1.
Dyslipidemia is common in insulin resistance and is characterized by fasting hypertriglyceridemia, low levels of HDL cholesterol and a delayed clearance of TG-rich lipoproteins, including very low density lipoproteins (VLDLs) (18, 19) . Recently, the mechanisms underlying the development of hypertriglyceridemia in patients with general and partial lipodystrophies have been reported (20, 21) . Hepatic VLDL production increases in patients with insulin resistance and partial lipodystrophy. In the case of Patient 1, the serum levels of fasting TG, apolipoprotein C2, C3 and E were high (data not shown), which indicated a high concentration of VLDLs in the blood. Such high levels of VLDLs cause increases in de novo lipogenesis in the liver. Therefore, the presence of VLDL remnants may be the primary cause of accelerated atherosclerosis in Patient 1.
Although the effects of thiazolidinediones on glycemic control appear to vary in patients with FPL (11, 17, (22) (23) (24) (25) (26) , pioglitazone treatment decreased the levels of HbA1c and fasting TG in the case of Patient 1. It is conceivable that pioglitazone improves glycemic control and triglycemic control by reducing the levels of free fatty acids (FFA) in venous effluent from adipose tissue and by limiting the lipotoxicity of other insulin-sensitive tissues, e.g. the liver and muscle (27, 28) . In Patient 1, pioglitazone not only increased fat mass, but also increased lean mass. Although the significance of increased lean mass is not known, we might speculate that pioglitazone improves glycemic control not only by inducing adipocyte differentiation, but also by increasing the lean mass.
In conclusion, we herein described a case of premature atherosclerosis in a Japanese diabetic patient with atypical FPL and hypertriglyceridemia. Pioglitazone was effective in controlling the blood glucose levels, TG and adiponectin. In this case, the sequencing of candidate genes LMNA, PPARG and CAV1, which are known to be associated with FPL, revealed no genetic abnormalities and therefore suggested that a novel gene may be involved. Although a cluster of atherogenic risk factors in a woman with FPL is likely to play a major role in atherosclerosis, other factors, including genes associated with FPL, might affect the development of atherosclerosis. Further studies should be performed in order to obtain additional clinical and genetic information to better understand the mechanisms underlying premature atherosclerosis in patients with FPL.
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